145 related articles for article (PubMed ID: 35612335)
1. New psychoactive substances and low-income countries: a burgeoning (and neglected) crisis.
Del Rio A
Clin Ter; 2022 May; 173(3):224-225. PubMed ID: 35612335
[TBL] [Abstract][Full Text] [Related]
2. The health threat of drugs of abuse adulteration by new psychoactive substances.
Minutillo A; Palmi I; Mastrobattista L
Clin Ter; 2019; 170(6):e425-e426. PubMed ID: 31696904
[TBL] [Abstract][Full Text] [Related]
3. New psychoactive substances: An actual problem or an overestimated phenomenon?
Vaiano F; Pascali JP; Bertol E
Forensic Sci Int; 2019 Nov; 304():109941. PubMed ID: 31574421
[TBL] [Abstract][Full Text] [Related]
4. New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard.
Zaami S
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9681-9690. PubMed ID: 31799633
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
Gray R; Bressington D; Hughes E; Ivanecka A
J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
[TBL] [Abstract][Full Text] [Related]
6. Air monitoring for illegal drugs including new psychoactive substances: A review of trends, techniques and thermal degradation products.
Gent L; Paul R
Drug Test Anal; 2021 Jun; 13(6):1078-1094. PubMed ID: 33870654
[TBL] [Abstract][Full Text] [Related]
7. New Psychoactive Substances: A Matter of Time.
Pantano F; Graziano S; Pacifici R; Busardò FP; Pichini S
Curr Neuropharmacol; 2019; 17(9):818-822. PubMed ID: 31577198
[TBL] [Abstract][Full Text] [Related]
8. The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review.
Orsolini L; Chiappini S; Corkery JM; Guirguis A; Papanti D; Schifano F
Expert Rev Neurother; 2019 Dec; 19(12):1253-1264. PubMed ID: 31503507
[No Abstract] [Full Text] [Related]
9. New/emerging psychoactive substances and associated psychopathological consequences.
Schifano F; Napoletano F; Chiappini S; Guirguis A; Corkery JM; Bonaccorso S; Ricciardi A; Scherbaum N; Vento A
Psychol Med; 2021 Jan; 51(1):30-42. PubMed ID: 31327332
[TBL] [Abstract][Full Text] [Related]
10. New psychoactive substances on dark web markets: From deal solicitation to forensic analysis of purchased substances.
Jurásek B; Čmelo I; Svoboda J; Čejka J; Svozil D; Kuchař M
Drug Test Anal; 2021 Jan; 13(1):156-168. PubMed ID: 32678972
[TBL] [Abstract][Full Text] [Related]
11. Public health surveillance of new psychoactive substances: recent developments.
Fitzgerald ND; Cottler LB; Palamar JJ
Curr Opin Psychiatry; 2024 Jul; 37(4):270-276. PubMed ID: 38587019
[TBL] [Abstract][Full Text] [Related]
12. Synthetic cathinones: an evolving class of new psychoactive substances.
Gonçalves JL; Alves VL; Aguiar J; Teixeira HM; Câmara JS
Crit Rev Toxicol; 2019 Aug; 49(7):549-566. PubMed ID: 31747318
[TBL] [Abstract][Full Text] [Related]
13. New psychoactive substances (NPS) prevalence over LSD in blotter seized in State of Santa Catarina, Brazil: A six-year retrospective study.
de Souza Boff B; Silveira Filho J; Nonemacher K; Driessen Schroeder S; Dutra Arbo M; Rezin KZ
Forensic Sci Int; 2020 Jan; 306():110002. PubMed ID: 31864775
[TBL] [Abstract][Full Text] [Related]
14. New psychoactive substances in Australia: patterns and characteristics of use, adverse effects, and interventions to reduce harm.
Sutherland R; Allsop S; Peacock A
Curr Opin Psychiatry; 2020 Jul; 33(4):343-351. PubMed ID: 32250983
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics in new psychoactive substance users: A single center study.
Su YJ; Chen TH; Liao WH; Chang KS; Lai YC
Medicine (Baltimore); 2023 Jun; 102(25):e34084. PubMed ID: 37352073
[TBL] [Abstract][Full Text] [Related]
16. New psychoactive substances in Taiwan: challenges and strategies.
Feng LY; Li JH
Curr Opin Psychiatry; 2020 Jul; 33(4):306-311. PubMed ID: 32167950
[TBL] [Abstract][Full Text] [Related]
17. Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project.
Corazza O; Assi S; Simonato P; Corkery J; Bersani FS; Demetrovics Z; Stair J; Fergus S; Pezzolesi C; Pasinetti M; Deluca P; Drummond C; Davey Z; Blaszko U; Moskalewicz J; Mervo B; Furia LD; Farre M; Flesland L; Pisarska A; Shapiro H; Siemann H; Skutle A; Sferrazza E; Torrens M; Sambola F; van der Kreeft P; Scherbaum N; Schifano F
Hum Psychopharmacol; 2013 Jul; 28(4):317-23. PubMed ID: 23881879
[TBL] [Abstract][Full Text] [Related]
18. Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014.
Neicun J; Yang JC; Shih H; Nadella P; van Kessel R; Negri A; Czabanowska K; Brayne C; Roman-Urrestarazu A
PLoS One; 2020; 15(10):e0241056. PubMed ID: 33125395
[TBL] [Abstract][Full Text] [Related]
19. New Psychoactive Substances: Evolution in the Exchange of Information and Innovative Legal Responses in the European Union.
Varì MR; Mannocchi G; Tittarelli R; Campanozzi LL; Nittari G; Feola A; Umani Ronchi F; Ricci G
Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33238595
[TBL] [Abstract][Full Text] [Related]
20. New psychoactive substances: challenges for drug surveillance, control, and public health responses.
Peacock A; Bruno R; Gisev N; Degenhardt L; Hall W; Sedefov R; White J; Thomas KV; Farrell M; Griffiths P
Lancet; 2019 Nov; 394(10209):1668-1684. PubMed ID: 31668410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
